GC Cell Past Earnings Performance
Past criteria checks 0/6
GC Cell's earnings have been declining at an average annual rate of -1.5%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 25% per year.
Key information
-1.5%
Earnings growth rate
-2.0%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 25.0% |
| Return on equity | -2.1% |
| Net Margin | -5.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share Price
Oct 14
Is GC Cell (KOSDAQ:144510) A Risky Investment?
Sep 08We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative
Mar 19We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its Debt
Feb 22Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?
Jan 18
Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?
Dec 14Revenue & Expenses Breakdown
How GC Cell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 184,444 | -10,708 | 25,841 | 25,002 |
| 31 Mar 24 | 186,623 | -6,802 | 24,353 | 25,045 |
| 31 Dec 23 | 187,544 | -174 | 23,132 | 24,681 |
| 30 Sep 23 | 182,085 | -10,813 | 23,641 | 27,611 |
| 30 Jun 23 | 186,192 | -6,589 | 22,577 | 26,449 |
| 31 Mar 23 | 194,327 | -946 | 23,635 | 27,279 |
| 31 Dec 22 | 236,120 | 26,537 | 23,284 | 26,426 |
| 30 Sep 22 | 262,621 | 51,819 | 22,393 | 23,260 |
| 30 Jun 22 | 251,382 | 52,690 | 21,601 | 21,514 |
| 31 Mar 22 | 224,848 | 50,939 | 16,598 | 19,388 |
| 31 Dec 21 | 168,310 | 31,422 | 12,618 | 18,490 |
| 30 Sep 21 | 121,231 | 15,404 | 6,681 | 17,282 |
| 30 Jun 21 | 106,810 | 8,733 | 3,786 | 16,564 |
| 31 Mar 21 | 97,619 | 9,518 | 3,187 | 14,795 |
| 31 Dec 20 | 85,562 | 4,160 | 2,808 | 13,961 |
| 30 Sep 20 | 75,083 | 2,256 | 2,954 | 12,672 |
| 30 Jun 20 | 65,762 | 599 | 2,808 | 13,698 |
| 31 Mar 20 | 60,762 | -1,670 | 2,642 | 14,696 |
| 31 Dec 19 | 57,895 | -2,276 | 2,354 | 15,110 |
| 30 Sep 19 | 55,920 | -421 | 1,932 | 13,641 |
| 31 Dec 18 | 50,620 | 1,002 | 2,214 | 9,558 |
Quality Earnings: A144510 is currently unprofitable.
Growing Profit Margin: A144510 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A144510 is unprofitable, and losses have increased over the past 5 years at a rate of 1.5% per year.
Accelerating Growth: Unable to compare A144510's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A144510 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A144510 has a negative Return on Equity (-2.09%), as it is currently unprofitable.